Retatrutide and Medicare Advantage: Coverage, Costs, and How to Access This Triple Agonist

What Is Retatrutide and Why Does It Matter for Medicare Beneficiaries?

Retatrutide is an investigational subcutaneous injectable peptide developed by Eli Lilly that activates three gut hormone receptors at once: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. No other drug in development or on the market targets all three pathways in a single molecule. This triple mechanism produced striking weight loss results in the phase 2 trial published in The New England Journal of Medicine, where the 12 mg dose group lost a mean of 24.2% of body weight at 48 weeks, compared with 2.1% in the placebo arm [1].

For Medicare Advantage enrollees, retatrutide represents both a promise and a regulatory puzzle. The drug could become the most effective anti-obesity medication ever approved. But MA plans build their formularies around FDA-approved drugs, and Medicare Part D carries a statutory exclusion for weight-loss medications that has blocked coverage of semaglutide and tirzepatide for obesity in most cases [2]. Whether retatrutide eventually lands on MA formularies depends on three variables: FDA approval, the labeled indication, and possible legislative changes to Part D's obesity drug exclusion.

Current FDA Status of Retatrutide

Retatrutide has not received FDA approval for any indication. The drug is in phase 3 clinical trials under Eli Lilly's TRIUMPH program, evaluating it for both obesity and type 2 diabetes [3]. Phase 3 enrollment has included trials for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, as well as trials in adults with type 2 diabetes who need better glycemic control.

The phase 2 dose-ranging study (N=338) randomized participants across five dose levels (1 mg, 4 mg, 8 mg, 12 mg maintenance doses) and placebo [1]. Results at 48 weeks showed dose-dependent weight loss:

• 1 mg group: 8.7% mean reduction
• 4 mg group: 17.1% mean reduction
• 8 mg group: 22.8% mean reduction
• 12 mg group: 24.2% mean reduction

That 24.2% figure exceeds the weight loss seen in key trials of both semaglutide 2.4 mg (14.9% in STEP 1, N=1,961) and tirzepatide 15 mg (22.5% in SURMOUNT-1, N=2,539) [4][5]. Phase 3 data will determine whether these results hold in larger, longer, more diverse populations.

No FDA advisory committee date or PDUFA target date has been publicly announced. Eli Lilly has stated that they expect to submit a New Drug Application based on TRIUMPH data, but specific timing depends on trial completion and regulatory interactions [3].

Why Medicare Advantage Plans Cannot Cover Retatrutide Today

The answer is short. MA plans only cover FDA-approved medications. Retatrutide is not FDA-approved. No Medicare Advantage plan, no Medicare Part D plan, and no Medigap supplement can cover an unapproved investigational agent.

This applies regardless of how your MA plan structures its pharmacy benefit. Whether your plan uses a closed formulary, an open formulary with prior authorization, or a specialty pharmacy tier, the drug must first carry an FDA-approved label. Trial participants may receive retatrutide at no cost through ClinicalTrials.gov-registered studies, but that is a clinical trial pathway, not an insurance benefit [3].

There is no off-label workaround. Physicians sometimes prescribe FDA-approved drugs off-label (tirzepatide for obesity before its SURMOUNT label, for example), and Part D plans may cover those uses. But retatrutide has no approved label at all, making even off-label prescribing impossible.

The Medicare Part D Obesity Drug Exclusion: The Bigger Problem

Even after FDA approval, retatrutide may face a coverage wall that has nothing to do with formulary decisions. The Social Security Act Section 1862(a)(1)(A) and implementing regulations have historically excluded drugs used for "anorexia, weight loss, or weight gain" from Medicare Part D coverage [2]. This is the same provision that has blocked Medicare coverage of semaglutide (Wegovy) when prescribed for obesity.

The Treat and Reduce Obesity Act has been introduced in multiple Congressional sessions, most recently as S.2407 in the 118th Congress, and would remove this exclusion [2]. As of May 2026, the bill has not been signed into law. Several bipartisan proposals have gained traction, and the Congressional Budget Office has scored various versions, but passage remains uncertain.

Here is how the coverage pathway breaks down for retatrutide under different scenarios:

Scenario 1: Approved for obesity only, no legislative change. Medicare Part D excludes coverage. MA plans with supplemental benefits could theoretically add weight-loss drug coverage using rebate dollars, but very few have done so. Out-of-pocket cost would likely mirror cash-pay pricing for the GLP-1 class (Wegovy lists at approximately $1,349/month as of 2026).

Scenario 2: Approved for type 2 diabetes (with or without obesity label). Part D must cover medically necessary diabetes treatments. Plans would add retatrutide to formularies, likely on a specialty tier with prior authorization requirements and step therapy (requiring failure of metformin, and possibly a GLP-1 RA, first). This is the same pathway tirzepatide (Mounjaro) used to gain Part D access for diabetes.

Scenario 3: Approved for obesity, and Congress passes the Treat and Reduce Obesity Act or equivalent. Part D could cover anti-obesity medications. Plans would still impose utilization management. Expect BMI thresholds, comorbidity documentation, prior authorization, and quantity limits.

Scenario 4: Approved for obesity with a cardiovascular risk-reduction indication (similar to semaglutide's SELECT trial indication). Some legal analysts believe a cardiovascular indication could bypass the obesity exclusion, since the drug is being prescribed for heart disease prevention rather than weight loss. CMS has not issued definitive guidance on this interpretation [6].

How the Treat and Reduce Obesity Act Could Change Everything

The single most important variable for Medicare coverage of retatrutide (and every GLP-1/GIP agonist) is Congressional action on the Part D obesity drug exclusion. The Treat and Reduce Obesity Act would add FDA-approved anti-obesity medications to the Part D benefit [2].

Supporters cite the CDC's data showing 42.4% adult obesity prevalence and argue that excluding effective treatments from the nation's largest insurer is medically indefensible [7]. Opponents point to CBO cost projections. Covering GLP-1 agonists for Medicare's roughly 67 million beneficiaries could cost tens of billions annually, depending on uptake assumptions and negotiated pricing under the Inflation Reduction Act's drug price provisions.

Even if the Act passes, implementation would take time. CMS would need to issue guidance, plans would need to update formularies, and prior authorization criteria would need development. A realistic timeline from passage to first-prescription coverage is 6 to 12 months.

What About Medicare Advantage Supplemental Benefits?

Some MA plans offer supplemental benefits beyond standard Medicare coverage, funded by plan rebate dollars. In theory, an MA plan could add anti-obesity medication coverage as a supplemental benefit even without a change to Part D law.

In practice, very few have done so. The cost exposure is too high. A single beneficiary on a GLP-1 agonist costs the plan $12,000 to $16,000 per year at list price. With millions of MA enrollees potentially eligible, plans have been reluctant to open this benefit category.

A small number of MA plans in 2025 and 2026 have offered limited weight-management benefits that include nutrition counseling, gym memberships, or behavioral health support. These do not include prescription anti-obesity medications. Check your plan's Evidence of Coverage (EOC) document for the most current supplemental benefit details, or call the number on your member ID card.

The Medicare Plan Finder tool at Medicare.gov lets you compare MA plan formularies by drug name. Once retatrutide receives FDA approval, you can search for it there to see which plans include it [8].

Preparing for Retatrutide Access: Steps You Can Take Now

You cannot get retatrutide through insurance today. But you can position yourself for faster access once the regulatory picture clarifies.

Step 1: Establish obesity or diabetes as a documented diagnosis. Ask your physician to formally code your condition. For obesity, the ICD-10 code is E66.01 (morbid obesity due to excess calories) or E66.09. For type 2 diabetes, it is E11.x. Insurance coverage of any anti-obesity or diabetes medication requires a documented, coded diagnosis in your medical record.

Step 2: Complete step-therapy requirements now. Most insurance plans, including future MA formularies, will require you to have tried and failed cheaper alternatives before covering a new branded injectable. Typical step-therapy requirements include metformin (for diabetes), lifestyle intervention documentation, and possibly a first-generation GLP-1 receptor agonist like liraglutide. Having these documented failures in your chart now means fewer delays later.

Step 3: Monitor clinical trial enrollment. The TRIUMPH program on ClinicalTrials.gov lists active and recruiting trials [3]. Trial participation gives you access to the drug at no cost, with regular medical monitoring. Ask your physician or a local academic medical center about eligibility.

Step 4: Track legislative developments. The American Obesity Association and the Obesity Action Coalition both maintain trackers for federal legislation affecting anti-obesity medication coverage. If the Treat and Reduce Obesity Act advances, Medicare coverage could follow within a year of passage.

Step 5: Review your MA plan during Annual Enrollment. The Medicare Annual Enrollment Period (October 15 through December 7) is your yearly opportunity to switch MA plans. If retatrutide gains approval, plans will update their formularies, and the best coverage option may differ from your current plan.

How Retatrutide Compares to Currently Available Alternatives

While waiting for retatrutide, several FDA-approved alternatives exist. Some carry Medicare coverage for specific indications.

Tirzepatide (Mounjaro/Zepbound): A dual GIP/GLP-1 agonist also from Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes and covered by Part D for that indication [9]. Zepbound carries the obesity indication. The SURMOUNT-1 trial showed 22.5% weight loss with the 15 mg dose at 72 weeks [5].

Semaglutide (Ozempic/Wegovy): A GLP-1 receptor agonist from Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes and covered by Part D [10]. Wegovy carries the obesity and cardiovascular risk-reduction indications. The STEP 1 trial demonstrated 14.9% weight loss at 68 weeks, and the SELECT trial (N=17,604) showed a 20% reduction in major adverse cardiovascular events [4][6].

Liraglutide (Saxenda/Victoza): An older GLP-1 agonist requiring daily injection. Less effective (approximately 8% weight loss in the SCALE trial) but sometimes used as a step-therapy prerequisite [11].

Retatrutide's triple-agonist mechanism adds glucagon receptor activation to the GIP/GLP-1 combination. Glucagon increases energy expenditure and promotes hepatic fat oxidation, which may explain the higher weight loss observed in phase 2 data and could offer particular benefit for patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The phase 2 trial showed that 86% of participants on the 12 mg dose with MASLD achieved normalization of liver fat (defined as <5% by MRI-PDFF) [1].

What About Compounded Retatrutide?

There is no legal compounded version of retatrutide. The drug has not been approved by the FDA, which means it cannot appear on the FDA's drug shortage list, and 503A/503B compounding pharmacies have no legal basis to produce it. Any website or pharmacy claiming to sell compounded retatrutide is operating outside federal law.

This differs from semaglutide and tirzepatide, which have appeared on the FDA drug shortage list at various points, temporarily allowing compounding pharmacies to produce copies under Section 503A/503B of the Federal Food, Drug, and Cosmetic Act [12]. Once a shortage resolves, the FDA expects compounders to stop production. Retatrutide has never been on any shortage list because it has never been a commercially available product.

Be extremely cautious with online vendors offering "research peptides" labeled as retatrutide. These products are unregulated, may contain incorrect doses or contaminants, and purchasing them for self-injection carries serious safety risks. The FDA's BeSafeRx program maintains a database of verified online pharmacies [12].

Realistic Cost Projections Once Approved

Eli Lilly has not announced pricing for retatrutide. Based on the company's pricing for tirzepatide and the broader GLP-1 class market, reasonable projections include:

• List price: $900 to $1,400 per month (Mounjaro lists at approximately $1,023/month; Zepbound at approximately $1,059/month as of 2026)
• With commercial insurance: $25 to $150/month copay depending on tier and plan
• Medicare Part D (if covered): Likely specialty tier with 25% to 33% coinsurance until the out-of-pocket maximum, followed by catastrophic coverage. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, total yearly cost would max at $2,000 [13]
• Cash pay without insurance: Likely similar to list price unless Eli Lilly offers a direct-to-patient discount program

The Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap, which took effect January 1, 2025, meaningfully changes the math for Medicare beneficiaries [13]. Even a specialty-tier drug with high coinsurance becomes affordable once the annual cap is reached, typically within the first few months of the year for an expensive injectable.